Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.

Détails

Ressource 1Télécharger: 35158822_BIB_B02180461EEC.pdf (340.83 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_B02180461EEC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Périodique
Cancers
Auteur⸱e⸱s
Teixeira Farinha H., Digklia A., Schizas D., Demartines N., Schäfer M., Mantziari S.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
22/01/2022
Peer-reviewed
Oui
Volume
14
Numéro
3
Pages
554
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
The management of esophageal cancer (EC) has experienced manifold changes during the last decades. Centralization of EC treatment has been introduced in many countries, subsequently allowing the development of specialized high-volume centers. Minimal invasive surgery has replaced open surgery in many centers, whereas more potent systemic treatments have been introduced in clinical practice. Newer chemotherapy regimens increase long-term survival. Nevertheless, the overall survival of EC patients remains dismal for advanced tumor stages. In this direction, a wide range of targeted biologic agents (immunotherapy) is currently under assessment. Anti- Human Epidermal Growth Factor Receptor-2 (HER-2) monoclonal antibodies are used in HER2 (+) tumors, predominantly well-differentiated adenocarcinomas, and are currently assessed in the neoadjuvant setting (TRAP, INNOVATION trials). Immune checkpoint inhibitors Nivolumab (ATTRACTION-03) and pembrolizumab (KEYNOTE-181), have demonstrated a survival benefit compared with conventional chemotherapy in heavily pre-treated progressive disease. More recently, CheckMate-577 showed very promising results for nivolumab in a curative adjuvant setting, improving disease-free survival mainly for esophageal squamous cell carcinoma. Several ongoing trials are investigating novel targeted agents in the preoperative setting of locally advanced EC. In addition, other immunomodulatory approaches such as peptide vaccines and tumor infiltrating lymphocytes (TILs) are currently under development and should be increasingly integrated into clinical practice.
Mots-clé
esophageal adenocarcinoma, immunotherapy, oesophageal cancer, squamous cell cancer, tumor microenvironment
Pubmed
Open Access
Oui
Création de la notice
19/02/2022 11:09
Dernière modification de la notice
23/11/2022 7:14
Données d'usage